नेविरापिन के इंटरैक्शन

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (आइवाब्राडिन लेबल, दवाओं के इंटरैक्शन)

Itraconazole ↓ Itraconazole Nevirapine and itraconazole should not be administered concomitantly due to potential decreases in itraconazole plasma concentrations that may reduce efficacy of the drug. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (इरिनोटेकन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (उपाडासिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (उब्रोजेपेंट लेबल, दवाओं के इंटरैक्शन)

Therapy with BARACLUDE is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) [see Warnings and Precautions (5.2) ] . (एंटेकाविर लेबल, बॉक्स्ड चेतावनी)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (एकालाब्रुटिनिब लेबल, दवाओं के इंटरैक्शन)

All other drug interactions shown are predicted. ↓ Atazanavir ↑ Nevirapine Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [See Warnings and Precautions (5. (एडेफोविर लेबल, बॉक्स्ड चेतावनी)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (एपिक्साबैन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (एप्रेमिलास्ट लेबल, चेतावनियां और सावधानियां)

Co-administration of nevirapine and efavirenz is not recommended as this combination has been associated with an increase in adverse reactions and no improvement in efficacy. (नेविरापिन लेबल, चेतावनियां और सावधानियां)

Co-administration of nevirapine and efavirenz is not recommended as this combination has been associated with an increase in adverse reactions and no improvement in efficacy. (नेविरापिन लेबल, चेतावनियां और सावधानियां)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (एबिराटेरोन लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (एल्पेलिसिब लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

If a CYP3A4 inducer is discontinued, consider OLINVYK dosage reduction and monitor for signs of respiratory depression. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

Ketoconazole ↓ Ketoconazole Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (कैबोज़ैंटिनिब लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] . (कैरिप्राज़िन लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (कोडीन लेबल, बॉक्स्ड चेतावनी)

Antiviral and antiretroviral drugs: Avoid concomitant use. (क्लैड्रिबिन लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of Strong CYP3A4 Inducers is not recommended. (क्लोज़ापिन लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. (ज़ोल्पिडेम लेबल, दवाओं के इंटरैक्शन)

• Avoid use with strong CYP3A inhibitors or CYP3A inducers. (टिकाग्रेलोर लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin): Avoid use of HETLIOZ in combination with rifampin or other CYP3A4 inducers, because of decreased exposure ( 7.2 , 12.3 ) (टैसिमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (टोल्वैप्टन लेबल, दवाओं के इंटरैक्शन)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use with strong CYP3A inducers if possible. (ट्रेटिनोइन लेबल, दवाओं के इंटरैक्शन)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (ट्रैबेक्टेडिन लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (डासाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (डेफ्लाज़ाकॉर्ट लेबल, दवाओं के इंटरैक्शन)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (डैरिडोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (डॉक्सोरूबिसिन लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

• CYP3A inducers: Avoid concomitant use. (ड्रोनेडेरोन लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (थायोटेपा लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (नालोक्सेगोल लेबल, दवाओं के इंटरैक्शन)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (नाल्डेमेडिन लेबल, दवाओं के इंटरैक्शन)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (निलोटिनिब लेबल, दवाओं के इंटरैक्शन)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (नॉरएथिस्टेरोन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

• CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (पाल्बोसिक्लिब लेबल, दवाओं के इंटरैक्शन)

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID. (पिमावैनसेरिन लेबल, दवाओं के इंटरैक्शन)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in meperidine plasma concentration. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

Strong CYP3A4 and P-glycoprotein (P-gp) inducers : Avoid using a strong inducer of CYP3A4 and/or P-gp during a dosing interval for ERZOFRI. (पैलिपेरिडोन लेबल, दवाओं के इंटरैक्शन)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (प्राज़िक्वांटेल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended. (नेविरापिन लेबल, चेतावनियां और सावधानियां)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (फ्लिबैनसेरिन लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Strong CYP3A4 Inducers: Avoid concomitant use. (बोर्टेज़ोमिब लेबल, दवाओं के इंटरैक्शन)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (बोसुटिनिब लेबल, दवाओं के इंटरैक्शन)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

CYP3A inducers: Do not use mifepristone with CYP3A inducers ( 7.3 ). (मिफेप्रिस्टोन लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (मैसिटेंटन लेबल, दवाओं के इंटरैक्शन)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (यूलिप्रिस्टल लेबल, चेतावनियां और सावधानियां)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (रिटलेसिटिनिब लेबल, दवाओं के इंटरैक्शन)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Therefore, co-administration with antiretroviral and anti-HCV drugs metabolized by CYP3A is not recommended or there may be a need to increase the dose of antiretroviral or anti-HCV drugs (see PRECAUTIONS-Drug Interactions ). (रिफाब्यूटिन लेबल, चेतावनियां)

Rifampin ↓ Nevirapine Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (रिमेजेपेंट लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (रिवारोक्साबैन लेबल, चेतावनियां और सावधानियां)

ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) (रैनोलाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (रोफ्लुमिलास्ट लेबल, चेतावनियां और सावधानियां)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (रोमिडेप्सिन लेबल, दवाओं के इंटरैक्शन)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (रोलापिटेंट लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (लुमाटेपेरोन लेबल, दवाओं के इंटरैक्शन)

Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. (लेडिपासविर और सोफोसबुविर लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (लैरोट्रेक्टिनिब लेबल, दवाओं के इंटरैक्शन)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (लोरलाटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. (ल्यूरासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (वाल्बेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (वेपडेजेस्ट्रेंट लेबल, दवाओं के इंटरैक्शन)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (सिरोलिमस लेबल, चेतावनियां और सावधानियां)

सेंट जॉन्स वॉर्ट HIV की कुछ दवाओं का खून में स्तर इतना घटा सकता है कि इलाज विफल हो जाए। (NCCIH, St. John's Wort)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (सोराफेनिब लेबल, दवाओं के इंटरैक्शन)

Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis Pancreatitis (including fatal cases) have occurred in patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine. (हाइड्रॉक्सीयूरिया लेबल, दवाओं के इंटरैक्शन)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

• Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. (अल्प्राज़ोलम लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (आइफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO. (आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary. (इमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (इमैटिनिब लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4/5 Inducers Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. (एक्सिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (एक्सेमेस्टेन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Alternatives to clarithromycin, such as azithromycin, should be considered. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure [see Clinical Pharmacology (12.3) ]. (एर्लोटिनिब लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ] . (एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (एस्ज़ोपिक्लोन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations. (एस्टाज़ोलम लेबल, चेतावनियां)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (ऑर्लिस्टैट लेबल, चेतावनियां और सावधानियां)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (ओन्डैनसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )]. (ओमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )] . (ओमेप्राज़ोल और सोडियम बाइकार्बोनेट लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

…Inducers of Hepatic CYP Enzymes Adults : When Caspofungin acetate for Injection is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of Caspofungin acetate for Injection should be considered [see Dosage and Administration… (कैस्पोफंगिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (क्लिंडामाइसिन लेबल, दवाओं के इंटरैक्शन)

Antibiotics: Clarithromycin ↓ Clarithromycin ↑ 14-OH clarithromycin Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

…several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. (क्लोमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiepileptics (AEDs) (Carbamazepine, Phenobarbital, and Phenytoin) Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate. (क्विनीन लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. (क्वेटियापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (ग्वानफेसिन लेबल, दवाओं के इंटरैक्शन)

Pharmacokinetic Interactions Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. (ज़िप्रासिडोन लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (ज़ेलेप्लॉन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers/inhibitors: Monitor for decreased tinidazole effect or increased adverse reactions ( 7.2 ) (टिनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (टैडालाफिल लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Strong Inducers of CYP 3A Clinical implication Coadministration of triazolam with strong inducers of CYP3A4 can significantly decrease the plasma concentration of triazolam and may decrease effectiveness of triazolam. (ट्रायज़ोलम लेबल, दवाओं के इंटरैक्शन)

Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (ट्रायमसिनोलोन लेबल, दवाओं के इंटरैक्शन)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (ट्रेप्रोस्टिनिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance . (डेक्सलैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (डॉक्सरकैल्सिफेरॉल लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

DRUG INTERACTIONS Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. (थायोथिक्सीन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (निंटेडानिब लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with esomeprazole magnesium may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with pantoprazole may reduce antiviral effect and promote the development of drug resistance. (पैंटोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Phenobarbital Clinical Impact: Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen. (फेनोप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (फेसोटेरोडिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of FOCINVEZ and concomitant drugs. (फोसाप्रेपिटेंट लेबल, चेतावनियां और सावधानियां)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (बेक्साग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (मिथाइलप्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (मिर्टाज़ापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Rifampin (Potent Inducer of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine and 600 mg of rifampin once daily for 7 days in 7 healthy Thai volunteers resulted in a decrease in the mean C max and AUC of mefloquine by 19% and 68%, respectively, and a decrease in the mean elimination half-life of mefloquine from 305 hours to 113 hours. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (मेमेंटिन और डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (रक्सोलिटिनिब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Fixed-Dose Combination of Efavirenz, Emtricitabine, and Tenofovir Once-weekly coadministration of 900 mg PRIFTIN with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine,… (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance. (रैबेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (रैमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (लिनाग्लिप्टिन लेबल, दवाओं के इंटरैक्शन)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (लिनाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance. (लैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (विलाज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Cancer Chemotherapy: Cyclophosphamide Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducers: Efficacy may be reduced ( 7.2 ). (सुवोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (सेलेजिलिन लेबल, दवाओं के इंटरैक्शन)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions, including adrenal crisis. (हाइड्रोकॉर्टिसोन लेबल, दवाओं के इंटरैक्शन)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Drugs that May Decrease Haloperidol Plasma Concentrations Coadministration of haloperidol with potent enzyme inducers of CYP3A4 may gradually decrease the plasma concentrations of haloperidol to such an extent that efficacy may be reduced. (हेलोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (एरिबुलिन लेबल, दवाओं के इंटरैक्शन)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (ग्लिसरॉल फिनाइलब्यूटिरेट लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (रिफैक्सिमिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (रियोसिगुआट लेबल, दवाओं के इंटरैक्शन)

Concurrent use of strong CYP3A inducers (e.g., St. (विन्क्रिस्टिन लेबल, दवाओं के इंटरैक्शन)

Antiretrovirals: atazanavir lopinavir ↑ voxilaprevir Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended. tipranavir/ritonavir ↓ sofosbuvir ↓ velpatasvir Coadministration is not recommended. (सोफोसबुविर और वेल्पाटासविर लेबल, दवाओं के इंटरैक्शन)

Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin). (एसेनापिन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (माइकाफंगिन लेबल, दवाओं के इंटरैक्शन)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)